Comment
doi: 10.1016/S1470-2045(21)00260-6.
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial
Affiliations
- PMID: 34197757
- DOI: 10.1016/S1470-2045(21)00260-6
Item in Clipboard
Comment
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial
Lancet Oncol.
2021 Jul.
No abstract available
Conflict of interest statement
GNM reports advisory boards support from Varian Medical Systems, Roche, and Merck Sharp & Dohme, outside the submitted work. IM reports advisory boards support from Eli Lilly, Novartis, Pfizer, and Roche, outside the submitted work.
Comment in
-
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial - Authors' reply.Lancet Oncol. 2021 Jul;22(7):e298. doi: 10.1016/S1470-2045(21)00355-7. Lancet Oncol. 2021. PMID: 34197758 No abstract available.
Comment on
-
Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial.Lancet Oncol. 2021 May;22(5):597-608. doi: 10.1016/S1470-2045(21)00080-2. Epub 2021 Apr 9. Lancet Oncol. 2021. PMID: 33845035 Clinical Trial.